Phyton Biotech has received Regulatory Approval from China’s NMPA for its plant cell fermentation-derived Paclitaxel Active Pharmaceutical Ingredient.

By |2021-05-26T17:47:45+00:00May 25th, 2021|

Phyton Biotech is pleased to announce approval from China’s regulatory body – National Medical Products Administration (NMPA) - for Phyton’s Drug Master File for paclitaxel active pharmaceutical ingredient produced via plant cell fermentation (PCF®).